CIBMTR answers clinically important questions using its Outcomes Database, Scientific Working Committees, other cellular and gene therapy initiatives, patient-reported outcomes, and collaboration with research partners.
CIBMTR explores how social factors, financial systems, care processes, and behavior affect access to and outcomes of cellular therapy. Current studies not only improve practice but also address barriers to treatment.
CIBMTR manages a repository of tissue samples from donors and recipients, both unrelated and related, to study the genetic, cellular, and immunologic factors that influence transplant outcomes.
CIBMTR develops and utilizes software tools and analytic methods to discover new patterns and biomarkers, predict clinical outcomes, facilitate cellular therapy matching, and model inventory sources to save and improve patient lives.
CIBMTR Biostatisticians provide advice and statistical consultation to researchers developing protocols for cellular therapy studies, and they investigate new statistical approaches and techniques for analyzing cellular therapy data.
CRO Services (formerly RCI BMT) supports trials of all phases with specific expertise in Phase I and Phase II trials.
The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) conducts multicenter Phase II and III trials with broad national participation.